Ticker
$VIR
1 catalyst touching VIR in the last 60 days, newest first, each with the price move that followed.
- 62
FDA grants Fast Track to VIR-5500 for metastatic prostate cancer
VIR-5500, co-developed with Astellas, received FDA Fast Track designation for late-line metastatic castration-resistant prostate cancer. Fast Track status accelerates review timelines and increases odds of regulatory success, though it is not a guarantee of approval and represents an earlier-stage milestone than Phase 3 data or NDA acceptance.
VIR ▲SEC 8-K · 8 Oct 2026, 12:38 UTC
Information only. AURA does not give buy or sell recommendations.